We are live on ! Find out more
PVCT

PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT

Delisted

PVCT was delisted on the 13th of October, 2016.

Back to rankings

4 hedge funds and large institutions have $8K invested in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in 2019 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 4 → 4 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

11% less capital invested

Capital invested by funds: $9K → $8K (-$1K)

Holders
4
Holders Change
–
Holders Change %
0%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
LIA
LBMC Investment Advisors
Tennessee
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
HFBOT
1
Home Federal Bank of Tennessee
Tennessee
$6K – – –
ACM
2
Academy Capital Management
Texas
$1K – – –
QCIG
3
Quad-Cities Investment Group
Iowa
$1K – – –
LIA
4
LBMC Investment Advisors
Tennessee
– -$1K -22,000 Closed

PVCT Hedge Fund Activity: Q2 2019 in Review

4 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) for Q2 2019, worth a combined $8K — down 11% from $9K a quarter earlier.

Fund positioning in PVCT was balanced in Q2 2019: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.

The largest seller was LBMC Investment Advisors, exiting entirely with an estimated $1K sold.

  • 4 institutional investors held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) as of Q2 2019, unchanged from Q1 2019.
  • Funds reported $8K of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) stock for Q2 2019, down 11% quarter-over-quarter.
  • 1 fund opened new PROVECTUS BIOPHARMACEUTICALS, INC. (DE) positions in Q2 2019 and 1 closed out, a net change of 0 holders.
  • The largest PROVECTUS BIOPHARMACEUTICALS, INC. (DE) seller in Q2 2019 was LBMC Investment Advisors, an estimated $1K sold.

Based on aggregated 13F filings for Q2 2019.